Why the study?
Ischemic mitral regurgitation commonly complicates pPCI in STEMI patients, and whether GDF11 influences IMR progression and prognosis is unknown.
Do pre-procedural serum GDF11 levels predict the progression of ischemic mitral regurgitation and heart failure risk in STEMI patients after pPCI?
Do pre-procedural serum GDF11 levels predict the progression of ischemic mitral regurgitation and heart failure risk in STEMI patients after pPCI?
Serum GDF11 serves as a prognostic biomarker in STEMI patients undergoing pPCI, where lower levels independently predict the exacerbation of ischemic mitral regurgitation and increased risk of post-procedural heart failure.
Answers are grounded in this paper and cite their sources.
May warrant intensified HF monitoring in low-GDF11 STEMI patients post-pPCI; extends prognostic biomarker research in IMR but is hypothesis-generating.
Ischemic mitral regurgitation (IMR) commonly complicates pPCI in STEMI patients. GDF11, a protective cardiovascular factor, may influence IMR progression and prognosis. Among 310 STEMI patients, 126 with recent normal echocardiography underwent pPCI with pre-procedural GDF11 testing. Cox regression, ROC analysis, and Spearman's correlation assessed GDF11's predictive value for IMR exacerbation and cardiac function. Lower GDF11 predicted IMR worsening (HR = 0.982, P = 0.004; AUC = 0.744, P < 0.001). High GDF11 patients had reduced IMR progression (P = 0.0013) and heart failure risk (P = 0.0003). GDF11 correlated with LVEF and left atrial changes (P < 0.05). Serum GDF11 independently predicts IMR exacerbation and post-pPCI heart failure, serving as a prognostic biomarker in STEMI.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: